Singular Health Group to Release 1 Million Shares from Voluntary Escrow on 25 July 2026

Details of the One Million Shares Exiting Voluntary Escrow on 25 July 2026

In its update dated 1 July 2026, Singular Health Group confirmed that precisely 1,000,000 fully paid ordinary shares currently held under voluntary escrow will be released on 25 July 2026. This disclosure complies with ASX Listing Rule 3.10A, which requires listed entities to notify the market promptly about forthcoming escrow releases, ensuring transparency for shareholders and potential investors alike.

Voluntary escrow agreements are typically established during an IPO or subsequent capital raising, with major shareholders, founders, or early investors agreeing to restrict share sales for a set period. The conclusion of such escrow periods is a routine aspect of a listed company’s lifecycle. Singular Health has explicitly stated that only one million shares are involved in this release, providing clear guidance to the market ahead of the scheduled date.

Clarifying Why the Escrow Release Does Not Affect Singular Health’s Issued Capital

The company emphasized that releasing these escrowed shares does not increase the total issued capital. This distinction is vital for investors: voluntary escrow does not create new shares but temporarily restricts existing shares from being traded. The one million shares are already part of the company’s total share count but have been locked from sale or transfer until the escrow period ends.

Once the escrow lifts on 25 July 2026, these shares will become freely tradable on the ASX. Therefore, no dilution occurs for current shareholders due to this release. The overall number of shares remains constant before and after the date. What changes is the amount of freely tradable shares, potentially affecting market liquidity and possibly short-term trading activity.

ASX Listing Rule 3.10A and Singular Health’s Disclosure Responsibilities

The notification was made under ASX Listing Rule 3.10A, which obliges entities to advise the ASX as soon as practicable after becoming aware that restricted securities are due for release from escrow. This rule ensures the market stays informed about changes in the freely tradable supply of shares, enabling investors to make well-informed decisions.

By issuing the update on 1 July 2026—about 24 days before the 25 July release—Singular Health provided advance notice, allowing investors and analysts to factor the upcoming release into their evaluations. This notification aligns with continuous disclosure obligations and reflects sound corporate governance for a company of Singular Health’s stature.

Singular Health’s Mission and the 3Dicom Software Platform

Singular Health Group positions itself as a medical technology company dedicated to building an integrated healthcare ecosystem focused on maximising the value of medical imaging records. Its strategy aims to enable universal access to imaging data and foster interoperability across healthcare systems to improve patient outcomes. This focus places the company within the expanding digital health and medical imaging technology sector, which is attracting growing interest from healthcare providers and investors worldwide.

The company’s core product suite revolves around its 3Dicom software solutions, designed to assist patients and medical professionals in visualising, communicating, and understanding medical imaging data more effectively. The platform transforms standard two-dimensional DICOM medical images—the common format used by modern imaging equipment—into immersive three-dimensional visualisations. This technology seeks to enhance the interpretation and sharing of medical imaging data within the healthcare ecosystem.

Significance of 3Dicom MD® US FDA Diagnostic Clearance

A key milestone noted in the company’s background is that 3Dicom MD® has obtained US Food and Drug Administration (FDA) clearance for diagnostic use. FDA clearance for diagnostic software is a stringent regulatory accomplishment, requiring proof that the software meets safety and effectiveness standards for clinical decision-making. For a company of Singular Health’s size and development stage, this clearance opens access to the large and commercially significant US healthcare market.

This FDA clearance permits licensed medical professionals in the US to use 3Dicom MD® to assist in clinical diagnoses, a higher regulatory standard than software approved solely for informational or educational purposes. For investors tracking Singular Health’s progress, this clearance is a crucial foundation for generating meaningful revenue in the US market. The current update did not disclose specific US revenue figures, customer counts, or commercial agreements.

Management and Investor Relations Contacts

The update was authorised by the Board of Directors of Singular Health Group. Managing Director and CEO Denning Chong is the primary contact, available at [email protected] or via the company’s main line at 1300 167 795. Investor relations inquiries should be directed to Paul Berson at [email protected] or +61 421 647 445.

This authorisation aligns with standard ASX continuous disclosure protocols. The presence of both an executive and an investor relations contact demonstrates Singular Health’s commitment to transparent communication with the investment community. Investors seeking further information on the escrow release or company strategy are encouraged to use these official channels.

Liquidity Considerations as One Million SHG Shares Become Freely Tradable

Although the escrow release does not change total issued capital, the availability of one million additional shares for trading on 25 July 2026 could influence market dynamics. Escrow releases sometimes lead to increased trading volumes if holders choose to sell shares, but shareholders may also retain their positions if confident in the company’s long-term outlook.

The impact of this release—one million shares—relative to Singular Health’s total shares outstanding and average daily volume will be key in determining market response. The company did not disclose the total shares on issue or the identities of shareholders whose shares are being released. At the time of publication, the immediate share price effect was unclear. Investors should monitor trading activity before and after 25 July 2026.

Singular Health’s Role in the ASX Medical Technology and Digital Health Sector

Operating within the broader digital health and health technology segment on the ASX, Singular Health develops software and platforms aimed at enhancing healthcare delivery. Its emphasis on medical imaging interoperability aligns with global trends toward integrated electronic health records, patient-centred care, and digital clinical workflows. These macroeconomic trends have attracted increasing investor interest in digital health both in Australia and internationally.

The company’s mission to unlock the full value of medical imaging records positions it as an infrastructure provider for the medical imaging industry rather than a competitor to imaging hardware manufacturers or radiology services. The 3Dicom platform is designed to integrate with existing imaging infrastructure, potentially facilitating faster adoption without requiring replacement of hospital or clinic equipment. The update did not disclose specific partnership, customer, or revenue details.

Investor Considerations Ahead of the 25 July 2026 Escrow Release

For current and prospective shareholders, the 25 July 2026 escrow release is an important upcoming corporate event. Beyond the share release, investors may look for related company announcements, such as operational updates, commercial progress of 3Dicom MD® in the US, or developments in the company’s healthcare ecosystem strategy.

Singular Health’s investor relations page at investors.singular.health serves as a central hub for tracking company developments. The company encourages contact through executive and investor relations channels. As with any ASX escrow release, market reaction will depend on the behaviour of released shareholders and broader sentiment toward Singular Health’s commercial execution and growth prospects.